Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

Autor: Bade RM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Schehr JL; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Emamekhoo H; Department of Medicine, University of Wisconsin-Madison, WI, USA., Gibbs BK; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Rodems TS; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Mannino MC; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Desotelle JA; Department of Medicine, University of Wisconsin-Madison, WI, USA., Heninger E; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Stahlfeld CN; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Sperger JM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Singh A; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Wolfe SK; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Niles DJ; Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA., Arafat W; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Steinharter JA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., Jason Abel E; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Beebe DJ; Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA., Wei XX; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., McKay RR; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Choueri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., Lang JM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2021 Sep; Vol. 15 (9), pp. 2330-2344. Date of Electronic Publication: 2021 Mar 03.
DOI: 10.1002/1878-0261.12931
Abstrakt: Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous nature of clear cell RCC (ccRCC), tumor biopsies provide limited clinical utility, but liquid biopsies could overcome these limitations. Prior liquid biopsy approaches have lacked clinically relevant detection rates for patients with ccRCC. This study employed ccRCC-specific markers, CAIX and CAXII, to identify circulating tumor cells (CTC) from patients with metastatic ccRCC. Distinct subtypes of ccRCC CTCs were evaluated for PD-L1 and HLA-I expression and correlated with patient response to therapy. CTC enumeration and expression of PD-L1 and HLA-I correlated with disease progression and treatment response, respectively. Longitudinal evaluation of a subset of patients demonstrated potential for CTC enumeration to serve as a pharmacodynamic biomarker. Further evaluation of phenotypic heterogeneity among CTCs is needed to better understand the clinical utility of this new biomarker.
(© 2021 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: